Results 51 to 60 of about 7,321 (205)
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT The vaginal microbiome plays a complex role in tenofovir's mucosal pharmacology. While the relative contribution of systemic versus local concentrations to PrEP PK/PD is an ongoing debate, the development of effective HIV prevention requires an understanding of events at the site of transmission.
Alyssa M. Lantz +4 more
wiley +1 more source
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients
, 2009 In order to assess the penetration of maraviroc to the central nervous system, we measured maraviroc concentrations in cerebrospinal fluid (CSF) and plasma.
Else, L +3 more
core +1 more source
, 2016 INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co ...
Moreno, S +9 more
core +2 more sources
Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV
American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik +5 more
wiley +1 more source
, 2013 In vitro efficacy of Maraviroc in MDM cultures. The bars represents the percentage of viral inhibition (p24 production pg/ml) in presence of Maraviroc, AMD3100 and AZT at different concentrations, considering the untreated as 100. Mean values of at least
Patrizia Saccomandi (431861) +11 more
core +1 more source
HIV/AIDS: Research and Palliative Care, 2010 Eva Poveda, Vincent SorianoDepartment of Infectious Diseases, Hospital Carlos III, Madrid, SpainAbstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection.
Eva Poveda, Vincent Soriano
doaj
Molecules, 2023 In this study, nine forced degradation products of maraviroc were found using chemometric analysis. This antiretroviral drug was subjected to photolytic, oxidative, as well as neutral, basic and acidic hydrolysis stress conditions.
Michał Wroński +3 more
doaj +1 more source
HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab
Journal of Medical Virology, Volume 98, Issue 4, April 2026.ABSTRACT The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P.
Lucie Poisson +6 more
wiley +1 more source
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract BACKGROUND There are currently no US Food and Drug Administration‐approved treatments for vascular dementia (VaD). Genome‐wide approaches have successfully identified druggable targets and treatments for various disorders. In this study, we performed druggable genome‐wide two‐sample Mendelian randomization (2SMR) analysis to identify possible ...
Matthew J. Lennon +4 more
wiley +1 more source
Antiretroviral treatment classes used with maraviroc.
, 2019 Antiretroviral treatment classes used with maraviroc.
Maurizio Zazzi (146810) +11 more
core +1 more source